New cell therapy trial targets hard-to-treat solid tumors
NCT ID NCT07242417
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new treatment called TC-G203 for people with GPC3-positive solid tumors that have come back or spread after other treatments. The main goal is to find the safest dose and see if the therapy can shrink tumors. About 30 adults aged 18-75 who have not responded to standard care will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GPC3 POSITIVE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Gobroad Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
-
GoBroad Healthcare Group
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 102206, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI platform aims to unlock Real-World cancer data on a massive scale
- Can a Dual-Action antibody outsmart advanced solid tumors?
- Can a genetic trait stop chemotherapy from working? a trial aims to fix that
- AI could outshine standard tumor measurements to predict survival
- New drug aims to fight skin cancer in transplant patients
- New imaging agent aims to light up hidden tumors